MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Cumberland Pharmaceuticals Inc

Затворен

4.27

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.04

Максимум

4.35

Ключови измерители

By Trading Economics

Приходи

-365K

-1.9M

Продажби

1.3M

10M

EPS

-0.136

Марж на печалбата

-18.223

Служители

91

EBITDA

-1.9M

-1.8M

Дивиденти

By Dow Jones

Следващи печалби

6.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-11M

62M

Предишно отваряне

4.27

Предишно затваряне

4.27

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Cumberland Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2025 г., 23:04 ч. UTC

Топ новини

JPMorgan Raises Risk of U.S., Global Recession to 60%

3.04.2025 г., 22:40 ч. UTC

Значими двигатели на пазара

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3.04.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3.04.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3.04.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3.04.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3.04.2025 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 21:43 ч. UTC

Топ новини
Печалби

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.04.2025 г., 20:43 ч. UTC

Пазарно говорене

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3.04.2025 г., 20:34 ч. UTC

Топ новини

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3.04.2025 г., 20:23 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3.04.2025 г., 19:21 ч. UTC

Пазарно говорене

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3.04.2025 г., 19:15 ч. UTC

Пазарно говорене

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Gold Drops In Tariff Fallout -- Market Talk

3.04.2025 г., 18:39 ч. UTC

Пазарно говорене

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3.04.2025 г., 18:38 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 18:30 ч. UTC

Топ новини

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3.04.2025 г., 18:20 ч. UTC

Пазарно говорене

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3.04.2025 г., 18:18 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:17 ч. UTC

Пазарно говорене

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3.04.2025 г., 18:04 ч. UTC

Пазарно говорене

US Sees More Job Openings in Construction, Transportation -- Market Talk

3.04.2025 г., 17:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cumberland Pharmaceuticals Inc Прогноза

Техническа оценка

By Trading Central

4.22 / 4.4Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.